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Abstract
The incidence of valvular aortic stenosis has increased over the past decades
due to improved life expectancy. Surgical aortic valve replacement is currently
the only treatment option for severe symptomatic aortic stenosis that has been
shown to improve survival. However, up to one third of patients who require
lifesaving surgical aortic valve replacement are denied surgery due to high
comorbidities resulting in a higher operative mortality rate. In the past such
patients could only be treated with medical therapy or percutaneous aortic
valvuloplasty, neither of which has been shown to improve mortality. With
advances in interventional cardiology, transcatheter methods have been
developed for aortic valve replacement with the goal of offering a therapeutic
solution for patients who are unfit for surgical therapy. Currently there are two
catheter-based treatment systems in clinical application (the Edwards SAPIEN
aortic valve and the CoreValve ReValving System), utilizing either a balloon-
expandable or a self-expanding stent platform, respectively. 
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Introduction
Rising life expectancy results in an increase in degenerative and
neoplastic diseases. Population-based observational studies have revealed
that 1% to 2% of patients older than 65 years have moderate to severe
aortic stenosis [1]. Surgical aortic valve replacement dates back to 1960
and is currently the only treatment option for severe aortic stenosis that
has been shown to improve survival, regardless of age [2]. In the ideal
candidate, surgical aortic valve replacement (AVR) has an estimated
operative mortality of 4% [2]. Unfortunately, up to one third of patients
with severe aortic stenosis (AS) are ineligible for corrective valve surgery,
either because of advanced age or the presence of multiple comorbidities
[3]. Current treatment options for those patients not offered surgery include
medical treatment and percutaneous balloon aortic valvuloplasty, though
neither has been shown to reduce mortality. Medically treated patients
with symptomatic AS have a 1- and 5-year survival of 60% and 32%,
respectively [4]. With the introduction of percutaneous aortic valve
implantation in 2002 there seems to be an alternative for these patients.
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Selection of patients
Due to the existence of the tried and tested
surgical valve replacement with good long-term
results the selection of patients for percutaneous
aortic valve implantation (PAVI), which should be
done with multidisciplinary consultation between
cardiologists, surgeons, imaging specialists and
anaesthesiologists, involves several critical steps [5].
Candidates considered for PAVI must have severe
symptomatic aortic stenosis in addition to a formal
contraindication to surgery or other characteristics
that would limit their surgical candidacy because
of excessive mortality or morbidity risk (Figure 1).
The procedure should be offered to patients who
have a potential for functional improvement after
valve replacement. It is not recommended for
patients who simply refuse surgery on the basis of
personal preference. 
Confirming the severity of aortic stenosis
Currently, PAVI is only indicated in patients with
calcified pure or predominant symptomatic aortic
stenosis. The different imaging modalities can assist
in the selection process by providing important
information on the aortic valve, coronary arteries,
and vascular structures. First, the severity of aortic
stenosis should be assessed. Both transthoracic
(TTE) and transoesophageal (TEE) Doppler echo  -
cardiography are the preferred tools to assess the
severity of aortic stenosis. In addition, the exact
anatomy of the aortic valve should be assessed.
Echocardiography, multi-slice CT (MSCT) and
magnetic resonance imaging (MRI) can all help to
distinguish between a bicuspid and a tricuspid
aortic valve. It is important to point out that
implantation of available percutaneous prostheses
is contraindicated in the case of a unicuspid or
bicuspid aortic valve, because of the risk of
incomplete deployment, significant paravalvular
regurgitation, and displacement of the prosthesis
[5, 6]. A severely calcified aortic valve may result in
the inability to cross the native valve with the
catheter. Bulky leaflets and calcifications on the free
edge of the leaflets may increase the risk of
occlusion of the coronary ostia during aortic valve
implantation. Therefore, the extent and exact
location of calcifications should be carefully
assessed before the implantation procedure. The
assessment of coronary anatomy is also important
in the selection process. Conventional coronary
angiography should be performed to exclude the
presence of significant coronary artery disease.
Conventional angiography remains the “gold standard”.
Figure 1. Algorithm to determine the treatment options of patients with severe aortic valve stenosis
AVA – aortic valve area, PAVI – percutaneous aortic valve implantation
Severe aortic stenosis:
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Transapical approach Subclavian approach
PAVI
Evaluation for PAVI
Assessment of patient risk according 
to clinical evaluation and using risk scores 
(e.g. EuroSCORE, STS score) 
in a multidisciplinary round
No contraindication for surgery Contraindication for surgery
Accepting the high risk
Accepting the 
poor outcome
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Analysis of surgery risk and evaluation of life
expectancy and quality of life
The precise evaluation of surgical risk in a specific
patient is not easy and involves an attempt at
individualisation based on statistical data from
databases containing a large number of procedures.
The most accepted and validated algorithms that
are widely available today are the EuroSCORE, the
STS (Society of Thoracic Score) and the Parsonnet
score. These algorithms predict the surgical risk by
assigning weight to various factors that affect the
clinical result, but it is clear that they can
underestimate or overestimate it in certain groups
of patients who are not represented satisfactorily in
the population used to generate the algorithm [7].
There is some evidence in the literature of incorrect
prediction of aortic valve replacement outcome using
the EuroSCORE model [8]. Osswald et al. report on
the real risk of overestimation of death by
EuroSCORE for patients undergoing isolated aortic
valve replacement, highlighting a possible incorrect
assignment of high-risk patients to the PAVI
procedure [9]. The key element to establish whether
patients are at high risk for surgery is multi  -
disciplinary clinical judgement, which should be used
in association with a more quantitative assessment,
based on the combination of several scores 
(for example expected mortality > 20% with the
EuroSCORE and > 10% with STS score). This
approach allows the team to take into account risk
factors that are not covered in scores but often seen
in practice such as chest radiation, previous aorto-
coronary bypass with patent grafts, porcelain aorta,
liver cirrhosis, etc. 
Assessment of feasibility and exclusion 
of contraindications for percutaneous aortic
valve implantation 
After criteria of severe symptomatic aortic valve
stenosis and high surgical risk are evaluated, the
technical evaluation of the patient’s suitability for
the percutaneous implantation technique begins
(Table I). The two most basic parameters are the
suitability of the peripheral arteries and the size of
the aortic valve annulus. Contrast angiography is
needed to assess the former, while the latter
requires an initial assessment of the diameter of
the aortic annulus on a TTE. In general terms,
a large artery with dominant elastic elements
should have a diameter up to 1 mm smaller than
the external diameter of the sheath that has to be
introduced for the valve implantation. Thus, current
systems with an external sheath diameter of 28 F
(SAPIEN 26 mm, Edwards), 25 F (SAPIEN 23 mm,
Edwards) and 22 F (CoreValve, Medtronic) require
minimum diameters in the order of 8 mm, 7 mm
and 6 mm, respectively. Apart from the minimum
diameter, the existence of significant vessel
Indication for percutaneous aortic valve implantation
Severe aortic stenosis (AVA: < 1 cm
2, mean gradient > 40 mmHg, severe symptoms)  
Contraindication for surgical valve replacement
Contraindication for percutaneous aortic valve implantation
Mild to moderate aortic stenosis
Asymptomatic patients
Life expectancy < 1 year
Surgical aortic valve replacement possible, but patient refused
Aortic anulus < 18 mm or > 25 mm (balloon-expandable) and < 20 mm or > 27 mm (self-expandable)
Bicuspid/unicuspid aortic valve
Asymetric heavy valvular calcification
Aortic root > 45 mm at the aorto-tubular junction
Presence of left ventricular apical thrombus
Contraindication for transfemoral approach
Severe calcification, tortuosity, small diameter of the iliac arteries
Previous aorto-femoral bypass
Severe angulation, severe atheroma of the aorta
Coarctation of the aorta
Aneurysm of the aorta with protruding mural thrombus
Contraindication for transapical approach
Previous surgery of the left ventricle using a patch
Calcified pericardium
Severe respiratory insufficiency
Non-reachable left ventricular apex
Table I. Currently proposed indications and contraindications for percutaneous aortic valve implantation
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tortuosity (> 90°), especially when combined with
wall calcifications, makes advancing the large
sheath problematic, with a high risk of vascular
complications that could potentially affect the final
outcome. In addition, the existence of extensive
circumferential calcifications limits the elastic
dilation of the artery; thus, the minimum diameters
referred to above are underestimated. Patients who
do not meet the criteria of suitable peripheral
arterial access may still be candidates for transapical
implantation. For the assessment of aortic annulus
diameter we should keep in mind that TTE
underestimates its size by a mean of 1.4 mm
compared to TEE [5, 10], while the latter method
also underestimates the size by 1.2 mm compared
with intraoperative measurement [10]. Therefore,
in order to avoid undesirable and often catastrophic
displacement of the prosthesis, there should be
a margin of at least 1-2 mm between the diameter
of the valve and the size of the aortic annulus
estimated using TEE, so that the former may be
successfully and safely anchored within the latter.
Computed tomography scan aortography and
angiography of the ascending aorta are the most
appropriate examinations for investigating these
aspects. Those examinations will also be used for
the measurement of the dimensions of the
ascending aorta and the aortic arch, which are
essential for checking eligibility for the CoreValve
(the most important being the diameter of the
ascending aorta, which should be < 4.3 cm). The
anatomy of the thoracic aorta (any chance of
porcelain aorta) and the abdominal aorta should be
studied by some imaging method for the existence
of extensive atheromatosis, mural thrombi and
aneurysm. 
Different transcatheter aortic valves
On the basis of the first results from clinical
trials, the CoreValve ReValving System and Edwards
Lifesciences System obtained the CE mark of
approval in 2007 with the specification that these
valves are intended for patients with a high or
prohibitive risk for surgical valve replacement or
who cannot undergo AVR. The first generation
balloon expandable valve was called the Cribier-
Edwards valve (Edwards Lifesciences Inc), whereas
at present the Edwards SAPIEN valve (Edwards
Lifesciences Inc) is commercially available (Figure 2).
The Edwards Lifesciences SAPIEN THV device is
a balloon-expandable valve. It consists of bovine
pericardium that is firmly mounted within a tubular,
slotted, stainless steel balloon-expandable stent.
Two valve sizes have been developed (23 mm and
26 mm). At present, available prosthesis sizes are
23 mm and 26 mm for aortic annulus diameters in
the range 18-22 mm and 21-25 mm, respectively.
The CoreValve ReValving device is a self-expanding
frame-valve prosthesis (Figure 2). It consists of
a porcine pericardial tissue valve that is mounted
and sutured in a multilevel self-expanding nitinol
frame. It is available in 26 mm and 29 mm sizes.
The device has a broader upper segment (outflow
aspect), which yields proper orientation to the blood
flow. The first generation valve used bovine
pericardial tissue and was constrained within 
a 25 French (F) delivery catheter. The second
generation valve was built with porcine pericardial
tissue within a 21 F catheter to allow access through
smaller diameter vascular beds. The third
generation of the device features a catheter with
a valve delivery sheath size of 18 F and a follow-on
shaft of 12 F. Newer devices that have first-in-man
application include Paniagua (Endoluminal
Technology Research, Miami, FL), Enable (ATS,
Minneapolis, MN), AoTx (Hansen Medical, Mountain
View, CA), Perceval (Sorin Group, Arvada, CO) Jena
(JenaValve Technology, Wilmington, DE), Lotus Valve
(Sadra Medical, Campbell, CA), and Direct Flow
percutaneous aortic valve (Direct Flow Medical, Inc.,
Figure 2. Profile of the Edwards SAPIEN Transcatheter Heart Valve (A) and CoreValve Revalving System (B)
A B
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Santa Rosa, CA). Percutaneous aortic valve
implantation represents a unique challenge for
anaesthesiologists. As with other invasive
procedures, a careful preoperative assessment,
appropriate intraoperative monitoring and imaging,
meticulous management of haemodynamics, and
early treatment of expected side effects and
complications are of utmost importance. An
unexpected decrease or increase in systemic
vascular resistance resulting in decreased coronary
perfusion pressure or acute heart failure by elevated
left ventricular end-diastolic pressure should be
avoided by maintaining a normotensive blood
pressure and heart rate between 60 bpm and 100
bpm. The choice of anaesthetic technique, either
local anaesthesia with mild sedation promoting
spontaneous respiration, deep IV sedation with
insertion of a laryngeal mask or general
anaesthesia, varies among centres and is probably
not associated with a significant difference in
outcome. Post valvuloplasty and implantation, done
under rapid right ventricular pacing to reduce left
ventricular ejection and cardiac motion, may require
some additional inotropic support. Tracheal
extubation can usually be performed at the end of
the procedure. Close postoperative monitoring is
necessary, and admission to an intensive care unit
is required. However, at present a retrograde
approach through the femoral artery is used. During
the procedure, balloon valvuloplasty is first
performed to facilitate passage of the native aortic
valve. During rapid right ventricular pacing, the
prosthesis is positioned and deployed under
fluoroscopy and echocardiographic guidance.
Alternatively, in patients with difficult vascular
access because of extensive calcifications or
tortuosity of the femoral artery or aorta,
a transapical approach can be used. After a partial
thoracotomy, direct puncture of the apical portion
of the left ventricular free wall is performed to gain
catheter access to the left ventricle and aortic valve.
The prosthesis is subsequently positioned and
deployed, similar to the antegrade approach. 
Results from the literature
Cribier-Edwards valve
Cribier  et al. performed the first human
implantation in 2002 [11]. In the Initial Registry of
EndoVascular Implantation of Valves in Europe 
(I-REVIVE) trial, followed by the Registry of
Endovascular Critical Aortic Stenosis Treatment
(RECAST) trial, a total of 36 patients (mean [SD]
EuroSCORE 12 [2]) were included [12] Twenty-seven
patients underwent successful percutaneous aortic
valve implantation (23 antegrade, 4 retrograde). The
30-day mortality was 22% (6 of 27 patients), and
the mean aortic valve area increased from 0.60
±0.11 cm
2 to 1.70 ±0.10 cm
2 (p < 0.001). Importantly,
this improvement in aortic valve area was
maintained up to 24 months follow-up [13]. After
these first trials, the Cribier-Edwards prosthesis and
the Edwards SAPIEN prosthesis have been used in
numerous studies. Overall, acute procedural success
is achieved in 75-100% of the procedures, and 
30-day mortality ranges between 8% and 50% in the
published studies. Using the transapical technique
and the SAPIEN valve, Walther has reported the
initial multicentre results of 59 consecutive patients,
which is the largest feasibility study published thus
far. Procedural success using the transapical
technique was achieved in 53 patients. Thirty-day
mortality was 13.6% and none of these were
thought to be valve related as there was good valve
function at autopsy [14].
CoreValve ReValving
Since the first implantation of the CoreValve
prosthesis in a patient in 2005 [15], a large number
of patients have been treated with this device to
date. The feasibility and safety of this valve was
studied in a prospective, multicentre trial. A total of
25 symptomatic patients with an aortic valve area
< 1 cm
2 were enrolled in the study. The device was
successfully implanted using the retrograde
technique in 22 of 25 patients. Procedural success
and aortic mean pressure gradients were markedly
improved immediately following implantations, with
pre-procedure gradients of 44.24 ±10.79 mmHg to
12.38 ±3.03 mmHg post-procedure, and were about
the same at 30-day follow-up (11.82 ±3.42 mmHg).
NYHA class improved by 1 to 2 grades in all patients.
Major adverse cardiac events (MACE; defined as
death from any cause, major arrhythmia, myocardial
infarction, cardiac tamponade, stroke, urgent or
emergent conversion to surgery or balloon
valvuloplasty, emergent percutaneous coronary
intervention, cardiogenic shock, endocarditis, or
aortic dissection) occurred in 8 of the 25 patients
while in the hospital [16]. Recently, Grube et al.
reported the results with the three different
generations of the CoreValve ReValving system. In
this non-randomised, prospective study, a total of
136 patients were included [17]. Ten patients were
treated with first generation devices, 24 patients
with second generation, and 102 patients with third
generation devices. At baseline, mean aortic valve
area was 0.67 cm
2 and mean logistic EuroSCORE
was 23.1% in the overall study population. Overall
procedural success rate increased significantly with
the new generation devices from 70.0% and 70.8%
to 91.2% for the first, second, and third generation
prostheses, respectively (p = 0.003). Interestingly,
periprocedural mortality decreased using newer
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devices from 10% (first generation) to 8.3% (second
generation) to 0% (third generation). Overall 30-day
mortality for the three generations was 40%, 8.3%
and 10.8%, respectively. Pooled data demonstrated
a significant improvement in mean NYHA functional
class (from 3.3 to 1.7, p < 0.001), without a difference
between the three generations. Importantly, NYHA
functional class and mean pressure gradient
remained stable up to 12 months follow-up in all
three generations. In addition, the results of
a multicentre registry with the third generation
CoreValve ReValving system have recently been
reported. A total of 646 patients from 51 centres
were included in the registry. It was a high-risk
elderly population (mean age 81 years) with a poor
functional class (85% of the patients in NYHA class
III or IV), and a high logistic EuroSCORE (mean
23.1%). Procedural success was achieved in 628 of
the 646 patients (97.2%). All-cause 30-day mortality
was 8%, and the combined end point of procedural
related death, stroke or myocardial infarction was
reached in 60 patients (9.3%). After successful
implantation, mean pressure gradient decreased
from 49 mmHg to 3 mmHg [18]. 
Conclusions
Percutaneous aortic valve implantation was
developed in order to provide an alternative and
less invasive method of treating aortic valve
stenosis. It has now been proven that the method
is feasible, with results that have been reproduced
by many physicians in many centres (approximately
8000 implantations to date). Today there are at
least 10 new percutaneous aortic valves that have
had their first implantation in humans, many more
that have reached the level of animal experiments,
and even more that are still in the initial design
stage. As a new treatment tool it has to be
evaluated in randomised controlled trials with long-
term follow-up in order to assess the safety and
efficacy. Therefore, the performance of PAVI should
be restricted to a limited number of high-volume
centres, which have both cardiology and cardiac
surgery departments, with expertise in structural
heart disease intervention and high-risk valvular
surgery. Due to the excellent results with surgical
valve replacement, patient selection, which should
be performed in multidisciplinary conferences, is of
utmost importance. Like other interventional
procedures, there is a learning curve with significant
improvements in the success rate and the clinical
results after the first 25 procedures, which implies
that the PAVI procedure should be initially
performed and thereafter supervised by a special
team [19, 20]. Beside the selection and intervention
of PAVI, close follow-up with assessment of clinical
and objective parameters is mandatory for defining
the indications of this technique.
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